events Archives - Page 5 of 7 - Sanford Burnham Prebys

Tag: events

Institute News

Early-career scientists showcase their work at the 20th Annual Trainee Research Symposium

AuthorMiles Martin
Date

October 5, 2021

People presenting scientific posters at an outdoor event with tents and trees in the background

The scientific leaders of tomorrow gathered to showcase their work at the 20th Annual Trainee Research Symposium on September 23rd. The talented group of presenters included postdoctoral researchers, graduate students, and staff scientists from labs across Sanford Burnham Prebys. 

After introductory remarks by Sanford Burnham Prebys Student Network co-chairs Stephen Sakuma and Marie Berenguer, PhD, as well as president Kristiina Vuori, MD, PhD, the young scientists gave 20-minute podium presentations about their research, which were judged by a panel of Sanford Burnham Prebys faculty and staff. Speakers included:

•    Nirmalya Dasgupta, PhD (Postdoctoral Fellow, Adams lab)
•    Ceda Stamenkovic (Graduate Student, Sacco Lab)
•    Cynthia Lebeaupin, PhD (Postdoctoral Associate, Kaufman lab)
•    James Kezos, PhD (Postdoctoral Fellow, Ocorr Lab)
•    Zhijie Xia, PhD (Postdoctoral Fellow, Freeze lab)
•    Valeria Guglielmi, PhD (Postdoctoral Associate, D’Angelo lab)
•    Victoria Recouvreux, PhD (Staff Scientist, Commisso lab)
•    Jonatan Matalonga Borrel, PhD (Postdoctoral Associate, Dong lab)
•    Chiara Nicoletti, PhD (Postdoctoral Associate, Puri lab)

Cynthia Lebeaupin, PhD and Valeria Guglielmi, PhD were respectively awarded first and second place by the judges for their presentations, for which they’ll each receive a cash prize to go towards career development activities. Lebeaupin’s research focuses on the progression of fatty liver disease to liver cancer, and Guglielmi studies the role of nuclear pores the development of bone marrow cells. 

After the first two sessions of presentations, the keynote speech for the Symposium was given by Katherine Thompson-Peer, PhD, an assistant professor of developmental & cell biology at the University of California at Irvine.

Following the last podium presentation was a poster session where 30 early-career scientists were given the chance to present their work. A panel of judges selected the top three posters—presented by Shaun Lim from the Kumsta and Hansen labs, Aleksandr Arzamasov from the Osterman lab, and Michaela Lynott from the Colas lab—and they will also receive a cash prize. The day was capped off with closing remarks from Sanford Burnham Prebys CEO C. Randal Mills, Ph.D.

Congratulations to all the participants in this year’s Symposium, and a special thank you to the staff at the Office of Education, Training, & International Services (OETIS) for organizing the event. 
 

Institute News

2021 Fishman Fund Award ceremony celebrates postdoctoral scholars

AuthorSusan Gammon
Date

September 28, 2021

Cynthia Lebeaupin, Valeria Guglielmi, and Paulina Sosicka

The Fishman Fund Awards were presented on September 23, 2021, in a virtual ceremony that honored the enduring legacy of our Institute’s founders, Dr. William and Lillian Fishman.

The three exceptional winners were welcomed by Fishman Fund co-founder Reena Horowitz; co-founder designee Jeanne Jones; and 2018 award recipient Laura Martin-Sancho, who commented, “A Fishman Fund Award is more than the money—it means that someone believes in you and believes in your goals.”

Longtime supporter, Institute trustee and namesake Malin Burnham reflected on his first meeting with the Fishmans more than 40 years ago when they were setting the stage for Sanford Burnham Prebys. “The Fishmans were creating a collaborative, inspirational atmosphere for postdocs—the lifeblood of scientific enterprise. This award pays tribute to their vision that young, talented scientists hold the key to curing disease.”

Sanford Burnham Prebys CEO Randy C. Mills thanked our supporters and shared, “Fishman Fund Award winners are on a journey not only to make their mark through scientific discovery, but also to define themselves as scientific leaders. I’m excited to see the vision of better science that they will translate into reality for the benefit of patients in need.”

Reena Horowitz and the late Mary Bradley established the Fishman Fund Awards in 2001 to honor the Fishmans and advance the careers of promising young scientists. Ever since the fund was launched 20 years ago, more than 70 awards have been conferred—now worth $10,000—to support career-development activities. 

This year’s awards were presented to:

Cynthia Lebeaupin, PhD
The Lenka Finca and Erna Viterbi Fishman Fund Prize

“I’m especially grateful to be affiliated with a community that supports its postdoctoral researchers, helping us transition into the great leaders of tomorrow.”

Dr. Lebeaupin is studying how fatty liver disease progresses to liver cancer. Fatty liver disease is rapidly increasing in the U.S. and around the world—and there is no cure. Studying how cells respond to stress conditions may open new avenues to target those responses and prevent cancer. Dr. Lebeaupin, a postdoctoral associate in the lab of Randal J. Kaufman, PhD, aims to become a professor of biology in academia.

Valeria Guglielmi, PhD 
The Reena Horowitz and Mary Bradley Fishman Fund Founders Award

“Now more than ever, we need people like you who trust scientists and believe science can really make a difference in our lives.”

Dr. Guglielmi is researching nuclear pore complexes and their role in the development and activity of immune cells. This research may lead to novel treatments for health conditions caused by dysregulated immune-cell production and function. Guglielmi is a postdoctoral associate in the lab of Maximiliano D’Angelo, PhD, and her goal is to become an independent investigator to further research on the immune system.

Paulina Sosicka, PhD 
The Jeanne Jones and Kathryn Fishback Fishman Fund Prize 

“I’m very grateful and honored to receive this Fishman Fund Career Development Award. Thank you to the founders and donors who made this possible.” 

Dr. Sosicka is investigating the application of dietary supplementation to treat debilitating genetic conditions called CDGs, which are rare diseases—mainly affecting children—caused by defects in the human enzymes and proteins responsible for adding sugar molecules onto proteins and lipids. The research may also provide insights into new approaches to treat obesity and cancer. A postdoctoral associate in the lab of Hudson Freeze, PhD, Dr. Sosicka aspires to become a professor in academia in the field of glycobiology.

 

Event recording

 

Institute News

Fighting rare diseases: Finding treatments and bringing hope to families

AuthorMonica May
Date

March 23, 2021

Hudson Freeze, PhD and José Luis Millán, PhD

The majority of rare diseases affect children, most of whom have an underlying genetic cause for their condition that is incurable.

The majority of rare diseases affect children, most of whom have an underlying genetic cause for their condition that is incurable.

Often, their own doctors have never heard of their disease, let alone know how to treat it.

But there is someplace they can turn to for help. The Human Genetics Program at Sanford Burnham Prebys provides insights into the genes and environmental factors that play a role in the development of childhood diseases. Their work often leads to better ways to diagnose, treat, and sometimes, even cure children.

On March 18, 2021, two patients whose lives were saved by discoveries made by Hudson Freeze, PhD, and José Luis Millán, PhD, joined the scientists for a conversation about what this work means to them and how their lives have been impacted. Watch the full discussion below.

Institute News

19th annual Trainee Research Symposium is a virtual success!

AuthorSusan Gammon
Date

October 5, 2020

Virtual Symposium on Zoom

Sanford Burnham Prebys’ annual Trainee Research Symposium is dedicated to highlighting the research of postdoctoral scientists and advanced graduate students.

This year, nearly 40 early-career scientists presented their research during an engaging two-day, jam-packed Zoom call that went off without a hitch.

After opening remarks by Malene Hansen, PhD, professor and faculty adviser for Postdoctoral Training, the podium and poster presentations began. Faculty, trainees, staff scientists and other interested parties navigated through sessions that ranged from new approaches to conquer brain cancer to the molecular basis of aging. The event gives “up-and-coming” scientists an opportunity to receive feedback on their work, explore potential new collaborations and receive prize money to support career development activities.

“We’re fortunate to be starting our careers at Sanford Burnham Prebys where the scientific research is significant and diverse,” says Cynthia Lebeaupin, PhD, a best poster presentation award winner. “I’m grateful to be able to present my project, which is focused on the link between fatty liver disease and cancer, to colleagues from different disciplines, such as cardiac disease and immunology. Their questions about my research bring fresh perspectives and spark new ideas.”

Keynote speaker Martin Chalfie, PhD, a Nobel Laureate in Chemistry and professor at Columbia University, opened day two of the event with a presentation titled, “GFP: Lighting Up Life,” detailing the journey that led to his discovery of GFP—a fluorescent protein that revolutionized how scientists look at the inner workings of living cells. Chalfie followed with an informal “Ask Me Anything” session where he shared his passion for mentoring early-career scientists.

C. Randal (Randy) Mills, PhD, CEO of Sanford Burnham Prebys, closed the event with a happy hour exclusively attended by trainee presenters—an opportunity for everyone to get to know more about his experiences as a PhD student and how his career evolved to his current position as leader of our world-class biomedical research Institute.

Many congratulations to all who participated in the symposium, and thanks to the organizers at the SBP Science Network and the Office of Education, Training, & International Services (OETIS).

This year’s symposium winners are:

Best Podium Talk – Judges Selection

Natalie Kirkland, PhD
Engler/Bodmer Labs
Runner-up
Stephen Sakuma
D’Angelo Lab

Honorable Mentions

Mallika Iyer
Godzik Lab
Jaime Zlamal, PhD
Osterman Lab

Best Poster –Judges Selection

Cynthia Lebeaupin, PhD
Kaufman Lab
Rashmi Mishra, PhD
Dong Lab
Ee Phie Tan, PhD
Hansen Lab

Best Podium Talk – Popular Vote

Stephen Sakuma
D’Angelo Lab

Honorable Mention

Jaime Zlamal, PhD
Osterman Lab

Institute News

Families, physicians and scientists unite at Sanford Burnham Prebys’ 11th Annual Rare Disease Day Symposium

AuthorMonica May
Date

March 16, 2020

Rare Disease Day group photo

This year’s event centered on CDG, a rare genetic condition that affects around 1,500 people worldwide.

With more than 270 attendees and 30 world-renowned scientists and clinicians, Sanford Burnham Prebys’ 11th Annual Rare Disease Day Symposium was officially the largest in the event’s history. This year’s discussion centered on congenital disorders of glycosylation, or CDG, a rare genetic condition that affects around 1,500 people worldwide.

Malin Burnham, T. Denny Sanford and Debra Turner, honorary trustees of Sanford Burnham Prebys, opened the three-day meeting with moving remarks. A theme emerged: Medical advances are accelerated when key stakeholders work together—including scientists, physicians, people with CDG and their families, patient advocacy groups, granting agencies, industry and philanthropists.

“Our annual symposium aims to create an ecosystem in which key stakeholders can collaborate and communicate,” said Hudson Freeze, PhD, director of the Human Genetics Program at Sanford Burnham Prebys and symposium chair. “Together, we celebrate our successes, focus on challenges and discuss the future of CDG research.”

Presenters at the meeting described the power of the ecosystem. Since the first conference a decade ago where scientists reported on the basic biology of CDGs, today we have promising clinical trials for the most common CDG mutation. In addition, a historic nationwide effort to establish the natural history of CDGs launched this year—which addresses decades of unresolved questions and helps remove barriers to starting clinical trials.

First discovered in the 1990s, scientists now know that CDG is caused by mutations that disrupt the body’s normal process of attaching sugars to proteins. Children with CDG have varying degrees of speech and language difficulty, poor balance, motor control, vision problems, hearing impairments and seizures. 

Because CDG is rare, many patients bounce between doctors and clinics for years before they receive an accurate diagnosis. At the symposium, an innovative session called the “Doctor-is-in” session connects families with medical researchers and clinicians in small groups. For some medical researchers, the session is the first time they have met a person with CDG.

The conference was co-organized by Sanford Burnham Prebys and CDG CARE, a nonprofit organization founded by parents seeking information and support for CDG.

Institute News

Starving the “world’s toughest cancer”

AuthorMonica May
Date

November 18, 2019

Moderator Andrea Decker of the Fleet Science Center; Darren Sigal, a clinician at Scripps Health; Russell Gold, a pancreatic cancer survivor; and Cosimo Commisso, a researcher at Sanford Burnham Prebys

Russell Gold is lucky to be alive. Only 9% of people with pancreatic cancer survive longer than five years—making it one of the deadliest cancers. This January, he will be a six-year survivor. 

To help the public better understand what makes pancreatic cancer so lethal—and how we can develop medicines so there are “more of me,” as Gold said—our Institute teamed up with the Fleet Science Center to host a panel discussion on Sunday, November 17. Gold was joined by a clinician and a scientist who both work on pancreatic cancer: Darren Sigal, MD, of Scripps Health; and Cosimo Commisso, Ph.D., an assistant professor at Sanford Burnham Prebys’ National Cancer Institute (NCI)-designated Cancer Center, respectively. 

As the speakers explained, pancreatic cancer is often difficult to diagnose because symptoms—such as pain in the abdomen, yellow skin and eyes, and weight loss—do not typically occur until the disease is advanced. As a result, pancreatic cancer is the 11th most common cancer but the second-leading cause of cancer death. More than 56,000 Americans are expected to receive a pancreatic cancer diagnosis in 2019, according to the American Cancer Society. 

Commisso, who was recently named a NextGen Star by the American Association for Cancer Research, is hopeful that his research will lead to effective treatments for pancreatic cancer. Commisso’s research focuses on how rapidly growing pancreatic tumors scavenge nutrients using an alternative supply route, called macropinocytosis. His lab has found that blocking this process, often described as “cellular drinking,” causes pancreatic tumors to shrink—indicating that the approach could lead to tumor-starving drugs. 

This event was the fourth of our five-part “Cornering Cancer” series. Register today to join us for a discussion on pediatric brain cancer in December.

Institute News

Top neuroscientists gather at Sanford Burnham Prebys’ annual symposium

AuthorMonica May
Date

November 18, 2019

Symposium organizers Jerold Chun (fourth from right), Randal Kaufman (second from left), Barbara Ranscht (third from right) and Huaxi Xu (far left), pose with the speakers

A mother who no longer remembers her son. A daughter who took doctor-prescribed pain medication and slipped into addiction. A father who has trouble grasping a pen and eventually becomes unable to walk. Neurological disorders are some of the most painful and complex conditions our society faces today. Yet much about the brain remains unknown, hindering our ability to help people with these disorders.

To help shed light on the brain’s mysteries, on November 1, 2019, more than 250 neuroscientists gathered at Sanford Burnham Prebys’ one-day symposium to share their latest discoveries. Organized by professors Jerold Chun, MD, PhD; Randal Kaufman, PhD; Barbara Ranscht, PhD; and Huaxi Xu, PhD, the event attracted scientists from around the world eager to learn more about biological clues that are leading to effective therapies. Read the full list of the invited speakers and their talks.

“Nearly every day we read about the toll neurological diseases such as Alzheimer’s, dementia, mental health disorders and more take on our society,” said Kristiina Vuori, MD, PhD, president of Sanford Burnham Prebys, in her introductory address. “Our symposium brings together scientists at the frontiers of brain research who share their latest discoveries to open new paths toward new and better treatments.”

More than 50 million Americans are affected by neurological disorders, including Alzheimer’s disease, dementia, addiction and more, according to the National Institute of Neurological Disorders and Stroke. Most of these conditions are not well addressed by current medicines.

At the symposium, world-renowned scientists from Stanford University, Mount Sinai, University of Vienna and other top-tier institutes gave talks describing their strategies to uncover the molecular basis of brain disorders and how these discoveries are advancing potential therapies. A national plan to address Alzheimer’s and other dementia types was described by Eliezer Masliah, MD, the National Institute of Aging’s director of the Division of Neuroscience.

“This was my first scientific conference, and it was perfect for learning about a wide range of cutting-edge brain research,” said attendee Jaclyn Beck, a PhD student at UC Irvine who studies the role of the brain’s immune cells, called microglia, in Alzheimer’s disease. “I have several pages of notes from the talks detailing findings I want to investigate and people I want to contact.”

For the past 40 years, our Institute has invited leading experts on one scientific topic to share their latest research at an annual symposium. By encouraging connection and collaboration, we hope to inspire insights that improve human health. The 41st annual symposium will take place in November 2020 and focus on the biology of organelles, specialized pouches within cells that carry out critical functions such as generating power and breaking down waste, and its role in health and disease.

Institute News

Advancing life-changing science at Sanford Burnham Prebys’ 2019 gala

AuthorMonica May
Date

November 13, 2019

From left to right: Honorary co-chairs Jeanne Jones and Reena Horowitz pose with our namesake Denny Sanford at our annual gala.

On November 2, 2019, more than 170 supporters of Sanford Burnham Prebys stepped into a winter wonderland at our Institute’s “Nordic Nights”-themed gala.

As attendees enjoyed the festivities—including an ethereal violinist on stilts and dancing ballerinas—the evening’s goal was never far from everyone’s mind: advancing biomedical research that will transform the future of human health. Thanks to guests’ generous donations our scientists can accelerate their efforts to understand and treat serious diseases such as Alzheimer’s, heart disease, cancer and more.

Watch Helen share her breast cancer story
(video shown at the gala)

Institute News

On the path to personalized breast cancer treatments

AuthorMonica May
Date

October 24, 2019

Fleet Cancer series-breast cancer

Ruth Claire Black wasn’t entirely surprised when she was diagnosed with breast cancer six and a half years ago. Her mother had died at age 52 of breast cancer, only two years after she was first diagnosed, Black explained at our recent Fleet Science Center event. New treatments have allowed Black’s story to differ from her mother’s—but as breast cancer experts from Sanford Burnham Prebys and UC San Diego Health explained, there is still a long way to go. 

“There is a great misconception that breast cancer is extremely easy to treat and is always cured. But the truth is that one in three women with early-stage breast cancer will relapse and eventually die from the disease,” said speaker Rebecca Shatsky, MD, a breast cancer oncologist at UC San Diego Health. “We are learning there aren’t one or two kinds of breast cancer—there are up to 30 different subtypes. To cure breast cancer, we need to look at treatments through a personalized lens.” 

Breast cancer is the second most common cancer in American women. One in eight women will be diagnosed with breast cancer in her lifetime, and more than 40,000 women die each year from the cancer. Targeted treatments—such as those that block the HER2 receptor—and hormone-based therapies have extended survival. However, 30% of people with estrogen-positive breast cancer, the most common form, eventually stop responding to standard-of-care treatments, for reasons that are largely unknown.

Speaker Svasti Haricharan, PhD, assistant professor at Sanford Burnham Prebys, is working to change these realities. Her work centers on a breast cancer subtype caused by defects in DNA repair machinery—a genomic “spell check” that normally corrects DNA copy errors during cell division. Nearly 20% of people who do not respond to breast cancer treatment have mutations in this machinery. Working with Shatsky, Haricharan’s team identifies breast cancer samples that have DNA damage repair defects. Then she tests these samples against thousands of FDA-approved treatments—with the goal of finding an effective treatment. 

For people like Black, these advances can’t come soon enough. 

“We have so much information about breast cancer. We have great diagnostics. Because of these tests, I know I’m a carrier of the BRCA2 mutation. I also know that it’s only a matter of time until my cancer returns,” said Black, who is a member of Sanford Burnham Prebys’ Community Advisory Board. “But doctors don’t know what to do with all of this information. That’s why I’m so supportive of the work taking place at Sanford Burnham Prebys. They are taking this information and doing something with it.” 

This event was the third of our five-part “Cornering Cancer” series. Register today to join us for discussions on pancreatic cancer in November and pediatric brain cancer in December. 
 

Institute News

Sanford Burnham Prebys welcomes U.S. Congressman Mike Levin

AuthorMonica May
Date

October 22, 2019

Congressman Mike Levin visits SBP

On October 1, 2019, U.S. Representative Mike Levin (D-CA) toured Sanford Burnham Prebys and met with several faculty members to learn more about the innovative biomedical research taking place in his backyard. Levin represents California’s 49th Congressional District, which includes North County San Diego, South Orange County and neighbors our La Jolla campus. 

The visit kicked off with a visit to a lab working to find medicines for a heart arrhythmia condition called atrial fibrillation (AFib), a disorder that hits home for Levin: His grandmother struggled with the disease. Levin peered into a microscope to view beating heart cells and learned how a team of experts from Sanford Burnham Prebys and Scripps Clinic are working to develop personalized treatments for the condition, which affects nearly six million Americans (meet the A-team.)

“Sanford Burnham Prebys is a great example of the vibrant biomedical research taking place in San Diego that has the potential to improve the quality of life for families across the country,” says Levin. “Seeing the Institute’s critical research up close and hearing firsthand how National Institutes of Health (NIH) funding has accelerated medical discovery only strengthens my commitment to supporting biomedical science. Following my visit to Sanford Burnham Prebys, I was proud to introduce legislation that would invest $10 billion in the NIH to support biomedical research, and I will continue to fight for this much-needed funding.”

Following the lab tour, Levin met with faculty members who—thanks to federally funded research—are working to find treatments for Alzheimer’s disease and addiction, and study the aging process to address age-related diseases such as cancer. The visit wrapped up in the lab of Hudson Freeze, PhD, the director of our Human Genetics Program, who studies a rare childhood disease called congenital disorders of glycosylation, or CDG. 

“Americans today are living longer and healthier lives because of federally funded medical research,” says Chris Larson, PhD, the adjunct associate professor of Development, Aging and Regeneration at the Institute who arranged the visit. “We are grateful that Mike took the time to sit down with us to learn about our NIH-funded work and how he can help support us on our mission to find cures for human disease.”

Editor’s note: Shortly after his visit Levin introduced legislation that calls for a $10 billion investment in biomedical research.